Wellesley, Mass., June 28, 2017 – Lumicell, a leader in the field of image-guided cancer surgery, today announced the appointment of Felix Geissler, M.D., Ph.D. as Chief Medical Officer. As a central member of Lumicell’s senior executive team, he will drive the clinical direction of the company and will work closely with the R&D and marketing teams to develop the overall business strategy.
Dr. Geissler previously held various roles within Sanofi Genzyme. Most recently, he was the medical head for the oncology department at Sanofi Genzyme and prior to that he was stationed in Tokyo as the CMO for the Asia-Pacific Region. Prior to Sanofi, Dr. Geissler worked for Novartis and BMS in various capacities. Before joining the pharmaceutical industry, Felix was a transplant surgeon at the UW Hospital in Madison, WI. He received his surgical training at the University of Leipzig, Germany where his focus was hepatobiliary and pancreatic surgery. During this time, he established a molecular research laboratory to identify circulating tumor cells. Felix received his M.D. from the Technical University of Munich and his Ph.D. from the University of Tubingen. During his academic tenure, he has published over 30 articles and several book chapters.
“Felix’s surgical expertise tied with his experience as a senior medical leader at Sanofi Genzyme, will be a huge asset to Lumicell and our expanding pipeline of surgical technologies,” said W. David Lee, CEO of Lumicell. “I am very pleased to welcome him to our expanding team.”
Every year more than 60,000 women undergoing lumpectomy must endure re-excision due to positive margins discovered on final histopathology examination. Second surgeries increase discomfort, add emotional and cosmetic expenses to the patient, and may cost the healthcare system close to $1 billion annually. Lumicell is working to address this unmet medical need.
About Lumicell, Inc.
Lumicell is a leader in the field of image-guided cancer surgery. The company is developing a revolutionary intraoperative margin assessment system that gives surgeons real-time visual feedback of residual cancer in the tumor bed. Lumicell’s surgical system includes a margin-targeted injectable optical contrast agent and a novel hand-held imaging device with exquisite single-cell detection. The unprecedented ability to see and remove all cancer cells during the initial surgery has the potential to significantly improve surgical outcomes and reduce healthcare costs by eliminating the need for repeat surgeries. Lumicell is investigating its cavity assessment system in patients undergoing surgery for breast cancer, sarcomas, and gastrointestinal cancer. Additional future indications may include surgeries for lung, prostate, ovarian, and brain cancers. For more information, please visit www.lumicell.com.
